Lytix Biopharma: Redeye Resumes Coverage

Research Note

2024-04-26

15:08

Through the completion of the equity issue, Lytix receives NOK50m before transaction costs. The issue was almost subscribed to the lower amount, with around 5% going to certain pre-committing shareholders and guarantors.

RR

Richard Ramanius

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.